The impact of dyslipidemia on prognosis of patients after endovascular abdominal aortic aneurysm repair

TL;DR

This study examines how dyslipidemia affects outcomes in patients who had a specific type of aortic surgery, finding it increases heart and stroke risks but may reduce a type of surgical complication.

Contribution

The study provides new insights into the specific effects of dyslipidemia on postoperative outcomes after endovascular aortic aneurysm repair.

Findings

Dyslipidemia did not affect all-cause mortality after EVAR.

Dyslipidemia increased the risk of major adverse cardiovascular and cerebrovascular events.

Dyslipidemia was associated with a lower incidence of type I endoleaks after EVAR.

Abstract

Dyslipidemia is common in patients with abdominal aortic aneurysm (AAA). However, there is insufficient research on the impact of dyslipidemia on the postoperative outcomes of patients with AAA after endovascular aortic aneurysm repair (EVAR). This study aimed to determine the impact of dyslipidemia on the prognosis of patients with AAA treated with EVAR.

We retrospectively reviewed patients with AAA who underwent EVAR at our hospital between 2010 and 2020. The baseline characteristics and prognoses of patients in the dyslipidemia and non-dyslipidemia groups were analyzed.

A total of 641 patients were included; the prevalence of dyslipidemia in patients with AAA was 42.3% (271/641), and the mean follow-up time was 63.37 ± 26.49 months. The prevalence of diabetes (10.0% vs. 15.1%, P = 0.050), peripheral arterial disease (17.3% vs. 25.8%, P = 0.018), and chronic kidney disease (3.0% vs. 6.3%, P = 0.043) was higher in the dyslipidemia group. The three-year all-cause mortality rate after EVAR was 9.98% (64/641), and there was no difference in the incidence of all-cause mortality (10.27% vs. 9.59%, P = 0.778) between the two groups. A total of 36 (5.62%) major adverse cardiovascular and cerebrovascular events (MACCEs) were observed within 3 years and were more common in patients with dyslipidemia (2.97% vs. 9.59%, P < 0.001). The incidence of stent-related complications in all patients was 19.97% (128/641), and there was no difference in the incidence of stent-related complications between the two groups (22.16% vs. 16.97%, P = 0.105); however, the incidence of type I endoleak in the dyslipidemia group was lower than that in the non-dyslipidemia group (9.19% vs. 4.06%, P = 0.012). Cox-regression analysis showed that high level of high-density lipoprotein cholesterol (HDL-C) was the protective factor (HR, 0.203, 95% CI, 0.067–0.616, P = 0.005) for MACCES, but it was the risk factor for type I endoleak (HR, 2.317, 95% CI, 1.202–4.466, P = 0.012).

Dyslipidemia did not affect the mortality of patients with AAA who underwent EVAR; however, it may increase the incidence of MACCEs. Dyslipidemia may decrease the incidence of type I endoleaks after EVAR; however, further studies are warranted. We should strengthen the postoperative management of patients with dyslipidemia, prevent the occurrence of MACCEs.

Figures

Patients inclusion and exclusion.

Accumulated rate of stent-related complications.

Accumulated rate of all-cause death.

Accumulated rate of major adverse cardiovascular and cerebrovascular events (MACCEs).

ROC analysis of TG, TC, HDL-C, and LDL-C compared to MACCEs and type 1 endoleak.

Tables

Table 1. Baseline of characteristics.

	Total cases (n = 641)	Non-dyslipidemia group (n = 370)	Dyslipidemia group (n = 271)	P-value*
Age, years	71.06 ± 8.56	71.42 ± 8.70	70.56 ± 8.37	0.807
Male	534 (83.3)	304 (82.2)	230 (84.9)	0.364
Smoke history	384 (59.9)	209 (56.5)	175 (64.6)	0.039
Hypertension	426 (66.5)	247 (66.8)	179 (66.1)	0.852
Diabetes mellitus	78 (12.2)	37 (10.0)	41 (15.1)	0.050
COPD	113 (17.6)	70 (18.9)	43 (15.9)	0.317
Carotid artery disease	25 (3.9)	16 (4.3)	9 (3.3)	0.517
Previous stroke	41 (6.4)	24 (6.5)	17 (6.3)	0.913
CAD	117 (18.3)	65 (17.6)	52 (19.2)	0.600
Previous PCI	77 (12.0)	43 (11.6)	34 (12.5)	0.722
PAD	137 (21.4)	67 (17.3)	70 (25.8)	0.018
CKD	28 (4.4)	11 (3.0)	17 (6.3)	0.043
Ruptured AAA	10 (1.6)	6 (1.6)	4 (1.5)	1.000
Neck diameter, mm	21.20 ± 2.78	21.22 ± 0.72	21.16 ± 2.86	0.592
Neck length, mm	28.28 ± 12.79	27.91 ± 12.46	28.78 ± 13.24	0.465
MAD, mm	54.84 ± 13.66	55.16 ± 13.07	54.40 ± 14.45	0.227
TG, mmol/L	1.58 ± 1.21	1.09 ± 0.38	2.24 ± 1.59	<0.001
TC, mmol/L	4.45 ± 1.20	4.15 ± 0.79	4.87 ± 1.50	<0.001
LDL-C, mmol/L	2.70 ± 0.97	2.47 ± 0.66	3.01 ± 1.21	<0.001
HDL-C, mmol/L	1.17 ± 0.35	1.30 ± 0.32	1.00 ± 0.32	<0.001

Table 2. Three-year follow-up outcomes.

	Total cases (n = 641)	Non-dyslipidemia group (n = 370)	Dyslipidemia group (n = 271)	P-value*
Duration (months)	63.37 ± 26.49	63.10 ± 26.89	63.75 ± 25.98	0.852
Death	64 (9.98)	38 (10.27)	26 (9.59)	0.778
AAA-associated death	8 (1.25)	5 (1.35)	3 (1.11)	1.000
MACCEs	37 (5.77)	11 (2.97)	26 (9.59)	<0.001
Cardiovascular event	26 (4.06)	10 (2.70)	16 (5.90)	0.042
Stroke	11 (1.72)	1 (0.27)	10 (3.69)	0.001
Stent-related complication	128 (19.97)	82 (22.16)	46 (16.97)	0.105
Type I endoleak	45 (7.02)	34 (9.19)	11 (4.06)	0.012
Type Ia endoleak	15 (2.34)	12 (3.24)	3 (1.11)	0.077
Type Ib endoleak	30 (4.68)	22 (5.95)	8 (2.95)	0.076
Type II endoleak	98 (15.29)	60 (16.22)	38 (14.02)	0.446
Type III endoleak	9 (1.40)	5 (1.35)	4 (1.48)	1.000
Displacement	1 (0.16)	1 (0.27)	0	1.000
Occlusion	8 (1.25)	3 (0.81)	5 (1.85)	0.293

Table 3. Univariate and multivariate analyses for predictors of follow-up outcomes.

Variable		Univariate analysis		Multivariate analysis
		HR (95% CI)	P-value	HR (95% CI)	P-value
MACCE	Diabetes mellitus	1.108 (0.432–2.842)	0.832
	PAD	1.044 (0.477–2.284)	0.914
	CKD	2.044 (0.628–6.656)	0.235
	Smoking history	0.867 (0.452–1.661)	0.666
	MAD	1.021 (1.000–1.044)	0.053	1.018 (0.996–1.040)	0.114
	TG	1.012 (0.783–1.308)	0.927
	TC	0.774 (0.569–1.053)	0.102
	HDL-C	0.181 (0.059–0.556)	0.003	0.203 (0.067–0.616)	0.005
	LDL-C	0.848 (0.589–1.222)	0.376
Type 1 endoleak	Diabetes mellitus	0.859 (0.339–2.176)	0.748
	PAD	0.939 (0.452–1.949)	0.866
	CKD	2.747 (0.983–7.679)	0.054	2.790 (0.979–7.950)	0.055
	Smoking history	0.500 (0.278–0.900)	0.021	0.529 (0.293–0.955)	0.034
	MAD	2.115 (1.179–3.795)	0.012	1.027 (1.009–1.047)	0.004
	TG	0.843 (0.600–1.185)	0.326
	TC	0.909 (0.704–1.173)	0.463
	HDL-C	2.170 (1.141–4.126)	0.018	2.317 (1.202–4.466)	0.012
	LDL-C	0.948 (0.697–1.288)	0.732
Death	Diabetes mellitus	1.037 (0.494–2.174)	0.924
	PAD	1.510 (0.875–2.603)	0.139
	CKD	1.661 (0.604–4.571)	0.326
	Smoking history	1.202 (0.721–2.003)	0.480
	MAD	1.016 (1.000–1.033)	0.055	1.012 (0.995–1.029)	0.156
	TG	0.734 (0.515–1.046)	0.087	0.838 (0.567–1.240)	0.378
	TC	0.581 (0.457–0.740)	<0.001	0.753 (0.376–1.506)	0.423
	HDL-C	0.520 (0.241–1.124)	0.096	0.690 (0.280–1.700)	0.420
	LDL-C	0.542 (0.395–0.745)	<0.001	0.792 (0.356–1.760)	0.567

Full text

Background

Abdominal aortic aneurysm (AAA) refers to the dilation of the abdominal aorta with a diameter greater than 3 cm (1, 2). It is more common in male smokers over the age of 65 years and other risk factors include dyslipidemia, hypertension, and other common risk factors for cardiovascular diseases (3, 4). Endovascular aortic aneurysm repair (EVAR) has become the main treatment for AAA due to its minimally invasive nature, excellent short-term and acceptable long-term prognosis (5). Endoleak is a common complication after EVAR, which refers to the continuous blood flow in the aneurysm sac after EVAR. Type I endoleak refers to incomplete sealing of the proximal aortic attachment site (IA) or distal iliac artery attachment site (IB). Type II endoleak is defined as the continuous filling of the aneurysm sac by the patent lumbar artery or inferior mesenteric artery, type III endoleak occurs when there is incomplete seal between components or component separation (6–8).

Dyslipidemia is common in patients with AAA. A previous study has shown that total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) play a role in the pathogenesis of AAA (9). Patients with small-diameter AAA may benefit from treatment that reduces LDL-C (10). High-density lipoprotein (HDL) reduction and dysfunction are also related to AAA formation (11). Dyslipidemia also affects the surgical treatment of AAA. A study pointed out that type II endoleak after EVAR for AAA is associated with dyslipidemia (12). However, there is still insufficient research on the impact of dyslipidemia on the postoperative outcomes of patients with AAA after EVAR.

Therefore, we conducted a retrospective study to screen patients with AAA with concomitant dyslipidemia and explore the impact of dyslipidemia on EVAR.

Methods

Patients

The medical records of 1,072 patients who received EVAR between 2010 and 2020 in our hospital were reviewed, and all patients with AAA who underwent EVAR were included, except for cases with: (1) The follow-up time less than three years or follow-up was lost; (2) The main diagnosis being abdominal aortic dissection or common iliac artery aneurysm. Finally, as shown in the Figure 1, 641 patients with AAA were included, and all patients were followed up by outpatient clinics or telephone for at least 3 years. The patients were divided into dyslipidemia and non-dyslipidemia groups based on whether they had dyslipidemia before EVAR. This study was approved by the ethics committee of West China Hospital, Sichuan University, the approve number was 20221827. The requirement for informed consent was waived due to de-identified patient information.

Patients inclusion and exclusion.

Data collection

We collected the anatomical parameters of AAA, including neck angle, neck length, and maximum diameter, by comparing contrast-enhanced computed tomography and angiography. We collected the surgical records and baseline characteristics of each patient through an electronic medical record system, including age, sex, underlying disease, and smoking history. We obtained the occurrence of death and major adverse cardiovascular and cerebrovascular events (MACCEs) through outpatient clinics or telephone calls and assessed stent-related complications using ultrasound or computed tomography angiography of the abdominal aorta. All patients were followed up at 1, 6, and 12 months after EVAR and once a year thereafter. Dyslipidemia was defined as a large range of lipid abnormalities or their combination of increased TC ≥ 6.20 mmol/L, LDL-C > 4.13 mmol/L, and triglyceride (TG) levels >2.25 mmol/L or decreased HDL-C < 1.03 mmol (13). We collected blood samples from all patients after fasting for 12 h to detect lipid levels based on the lipid levels of the local population and defined dyslipidemia as the presence of any of the following criteria: (1) Blood TG level of >1.83 mmol/L; (2) Blood TC level of >5.70 mmol/L; (3) Blood LDL-C level >4.0 mmol/L; (4) Blood HDL-C level <0.90 mmol/L, or a combination of these features. Stent-related complications included endoleaks, stent displacement, and stent occlusion. Type I endoleak includes type Ia and type Ib endoleaks, while type II includes transient and persistent endoleaks. MACCEs include newly developed coronary artery disease (CAD), myocardial infarction (MI), and stroke after EVAR. Aneurysm-related death was defined as death within 30 days of EVAR or death associated with stent-related complications.

Stent-related complications were the primary outcome, and secondary outcomes included MACCEs and all-cause mortality.

Statistical analysis

Statistical analysis was performed using SPSS, version 25, IBM. Continuous variables were represented as mean ± standard deviation (X ± SD) and compared using independent sample t-tests or Mann–Whitney U-test. The categorical variables were expressed as percentages and compared using χ^2^ tests. Endpoint events were analyzed using Kaplan–Meier survival curves. Cox regression model was used to evaluate the impact of each predictive factor on outcomes, we selected predictive factors with a univariate analysis P-value <0.1 for multivariate analysis to assess the independent effect of each predictor. Two-sided P < 0.05 was considered statistically significant.

Results

Baseline characteristics

As shown in Table 1, 271 (42.3%) of the 641 patients with AAA had concomitant dyslipidemia. The average age of patients with AAA was 71.06 ± 8.56 years old, with male patients accounting for 82.3%. Patients in the dyslipidemia group had a higher smoking history rate (56.5% vs. 64.6%, P = 0.039). There was no statistically significant difference in the rates of hypertension (66.8% vs. 66.1%, P = 0.852), chronic obstructive pulmonary disease (18.9% vs. 15.9%, P = 0.317), carotid artery disease (4.3% vs. 3.3%, P = 0.517), previous stroke (6.5% vs. 6.3%, P = 0.913), CAD (17.6% vs. 19.2%, P = 0.600), and previous percutaneous coronary intervention (11.6% vs. 12.5%, P = 0.722) between the two groups. The prevalence of diabetes (10.0% vs. 15.1%, P = 0.050), peripheral arterial disease (17.3% vs. 25.8%, P = 0.018), and chronic kidney disease (CKD) (3.0% vs. 6.3%, P = 0.043) was higher in the dyslipidemia group than in the non-dyslipidemia group. There was no significant difference in anatomical parameters such as neck diameter (21.22 ± 0.72 vs. 21.16 ± 2.86, P = 0.869), neck length (27.91 ± 12.46 vs. 28.78 ± 13.24, P = 0.278), and maximum diameter of the AAA between the two groups. The plasma TG (1.09 ± 0.38 vs. 2.24 ± 1.59, P < 0.001), TC (4.15 ± 0.79 vs. 4.87 ± 1.50, P < 0.001), and LDL-C (2.47 ± 0.66 vs. 3.01 ± 1.21, P < 0.001) of patients in the dyslipidemia group were significantly higher than those of non-dyslipidemia group, while HDL-C (1.30 ± 0.32 vs. 1.00 ± 0.32, P < 0.001) was significantly lower in the dyslipidemia group.

Follow-up outcomes

As shown in Table 2, all patients were followed up for more than three years, with an average follow-up time of 63.37 ± 26.49 months. There was no difference in follow-up time between the two groups (63.10 ± 26.89 vs. 63.75 ± 25.98, P = 0.760).

Stent related complications

A total of 128 (19.97%) patients experienced stent-related complications, including 82 (22.16%) in the non-dyslipidemia group and 46 (16.97%) in the dyslipidemia group. Among all complications, the incidence of type II endoleak was the highest (98/641, 15.29%), and its incidence between the two groups was comparable (16.22% vs. 14.02%, P = 0.446). This was followed by type Ib endoleak (30/641, 4.68%) with comparable incidence between the two groups (5.95% vs. 2.95%, P = 0.076). Only nine type III endoleaks were observed, and there was no difference in the incidence between the two groups (1.35% vs. 1.48%, P = 1.00). A total of 45 (7.02%) type I endoleaks were observed, and the incidence of type I endoleaks in the dyslipidemia group was lower than that in the non-dyslipidemia group (9.19% vs. 4.06%, P = 0.012). After observing the simultaneous occurrence of various types of endoleaks in some patients, 152 endoleaks were noted. One stent displacement and eight iliac branch occlusions were observed. There was no significant difference in the rate of stent-related complications (22.16% vs. 16.97%, P = 0.105) between the two groups, except for type I endoleak. However, as shown in Figure 2, the incidence of stent-related complications in the non-dyslipidemia group was slightly higher than that in the dyslipidemia group.

Accumulated rate of stent-related complications.

Mortality

The all-cause mortality rate 3 years after EVAR was 9.98% (64/641). The rate of aneurysm-related death was 1.23% (8/641). From Figure 3, it can be seen that the all-cause mortality rates of the two groups were similar. There was no significant difference in all-cause mortality between the two groups (10.27% vs. 9.59%, P = 0.778).

Accumulated rate of all-cause death.

MACCEs

A total of 37 (5.77%) MACCEs were observed within 3 years, including 26 cardiovascular events and 11 strokes. The incidence of MACCEs (2.97% vs. 9.59%, P < 0.001) in the dyslipidemia group were higher than that in the non-dyslipidemia group. Moreover, as shown in Figure 4, the difference in the incidence of MACCEs between the 2 groups gradually increased within 3 years after EVAR.

Accumulated rate of major adverse cardiovascular and cerebrovascular events (MACCEs).

Analysis for follow-up outcomes

As shown in Table 3 and Figure 5, multivariate analysis showed that high level of HDL-C was the protective factor (HR, 0.203, 95% CI, 0.067–0.616, P = 0.005) for MACCES, but it was the risk factor for type I endoleak (HR, 2.317, 95% CI, 1.202–4.466, P = 0.012), ROC analysis showed that the level of HDL-C can be used to predict Type I endoleak (AUC = 0.601). Smoking history was the protective factor (HR, 0.529, 95% CI, 0.293–0.955, P = 0.034) for type I endoleak, the larger MAD was the risk factor (HR, 1.027, 95% CI, 1.009–1.047, P = 0.004) for type I endoleak.

ROC analysis of TG, TC, HDL-C, and LDL-C compared to MACCEs and type 1 endoleak.

Discussion

Dyslipidemia includes a series of lipid abnormalities that may involve elevated TG, TC, and LDL-C levels or a decrease in HDL-C (13). There are regional differences in blood lipid levels, which are related to economic level and dietary structure (14). Our definition of dyslipidemia was based on the distribution of blood lipid levels in the population of our region, which may differ from the blood lipid limit values of other institutions for dyslipidemia. Due to the population distribution characteristics of patients with AAA, dyslipidemia is a common risk factor and comorbidity of AAA (15, 16). A previous study reported an 47.5% incidence of dyslipidemia in patients with AAA, close to 42.3% reported in our study (12). Patients with CKD have a characteristic lipid pattern of hypertriglyceridemia and reduced level of HDL-C (17), which were also often seen in patients with diabetes (18). Smoking is widely recognized as a risk factor for dyslipidemia (19), and dyslipidemia is a risk factor for peripheral artery disease (20). As shown in Table 1, the rates of CKD (3.0% vs. 6.3%, P = 0.043), diabetes (10.0% vs.15.1%, P = 0.050), smoking history (56.5% vs. 64.6%, P = 0.039), and PAD (17.3% vs. 25.8%, P = 0.018) in the dyslipidemia group were higher than those in the non-dyslipidemia group. Our study outcomes were consistent with the above viewpoints. Dyslipidemia is an important risk factor for CAD and stroke (13, 21), which is consistent with our study outcome that the dyslipidemia group had a higher rate of MACCEs (2.97% vs. 9.59%, P < 0.001), but there was no difference in the incidence of preoperative CAD (17.6% vs. 19.2%, P = 0.517), PCI (11.6% vs.12.5%, P = 0.722) and stroke (6.5% vs. 6.3%, P = 0.913) between the two groups.

Dyslipidemia is more common among people in high-income countries; however, due to dietary structure changes worldwide, its prevalence is increasing, even in low-income countries, particularly in rapidly developing China (14, 22, 23). In the future, the proportion of concomitant dyslipidemia in patients with AAA is predicted to increase. There is still a lack of research on the impact of dyslipidemia on the prognosis of patients with AAA after EVAR. This may be the first study conducted in southwestern China to explore the impact of dyslipidemia on the prognosis of patients with AAA after EVAR. Our study outcomes show that dyslipidemia will not increase the all-cause mortality incidence (10.27% vs. 9.59%, P = 0.778) and overall stent-related complications incidence (22.16% vs. 16.97%) in patients with AAA who underwent EVAR, but it will increase the risk of MACCEs (2.97% vs. 9.59%, P < 0.001) in patients with AAA who underwent EVAR, specially, it will increase the risk of type I endoleak in patients with AAA who underwent EVAR (9.19% vs. 4.06%, P = 0.012), ROC analysis also showed that the level of HDL-C can be used to predict Type I endoleak (AUC = 0.601). Currently, research on the effects of dyslipidemia on the formation of type I endoleak after EVAR is limited, why elevated HDL-C increased the risk of type I endoleak was unclear, there may be a lack of theoretical basis to explain it, this may also be a coincidence limited to statistics, and we need more researches to explore it. The relationship between elevated HDL-C levels and MACCEs risk is still controversial (24, 25), our study outcome suggested that high level of HDL-C was the protective factor (HR, 0.203, 95% CI, 0.067–0.616, P = 0.005) for MACCES, the larger MAD was the risk factor (HR, 1.027, 95% CI, 1.009–1.047, P = 0.004) for type I endoleak, which was consistent with the outcome of previous study (26). Why patient with smoking hirtory had a lower risk of type I endoleak (HR, 0.529, 95% CI, 0.293–0.955, P = 0.034) was unclear, this may be related to patients strictly quitting smoking and staying away from second-hand smoking environments after surgery.

A study pointed out that type II endoleak in patients with AAA after EVAR was associated with dyslipidemia (12); however, the main risk factors for type II endoleak include patent inferior mesenteric artery and patent lumbar artery (27, 28) Whether type II endoleaks can affect the formation of type II endoleaks after EVAR remains to be confirmed. The incidence of type II endoleaks in our study was 15.29%, which was lower than the 19.2% reported in a previous study (29), as shown in Table 2. There was no difference in the incidence of type II endoleaks between the two groups (16.22% vs. 14.02%, P = 0.446). In addition, dyslipidemia is closely related to atherosclerosis (30, 31), which also affects the lumbar and inferior mesenteric arteries. It may influence the patency of these arteries and may even reduce the incidence of type II endoleaks. The incidence of type III endoleaks, stent displacement, and iliac branch occlusion was low because of advancements in material technology and surgical techniques. The 2021 Canadian Cardiovascular Society Guidelines state that patients with AAA, dyslipidemia, and clinical atherosclerosis can benefit from statin therapy (32). Each patient with dyslipidemia was advised to take statins after EVAR, even after receiving treatment with statins, some patients' blood lipid levels were not well controlled, which may have been caused by irregular medication use, TG-rich lipoproteins and LDL particles were found to play key roles in the onset and development of cardiovascular disease (33, 34), we can see the incidence of MACCEs after EVAR was still significantly higher in the dyslipidemia group. Furthermore, many patients with dyslipidemia do not make dietary adjustments. For patients with dyslipidemia, more comprehensive management and treatment are needed, and it is imperative to monitor patients in order to prevent the transition to a state of dyslipidemia, with patient compliance playing a pivotal role.

Our study has a few limitations. First, this was a single-center retrospective study with small sample size. Second, due to the interval between postoperative follow-up examinations, records of endoleak occurrence time points may be inaccurate. Third, the completion of statin treatment in patients with dyslipidemia after EVAR has not been effectively monitored. Fourth, many patients do not return to the hospital for follow-up as planned, resulting in many patients being lost during midway visits; thus, postoperative management needs to be strengthened.

Conclusion

Dyslipidemia does not affect the mortality of patients with AAA who undergo EVAR but may increase the incidence of MACCEs. Dyslipidemia may decrease the incidence of type I endoleaks after EVAR; however, further studies are warranted. We should strengthen the postoperative management of patients with dyslipidemia, prevent the occurrence of MACCEs.